Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Finerenone continues to impress in diabetic kidney disease space: GlobalData
New data confirms Kerendia’s kidney and heart benefits hold strong in diabetic CKD patients, regardless of early eGFR dips, easing…
Optimising project management in pharma: 8 steps toward efficiency
Martin Kesselgruber, VP Global Project Management, Bachem, shares key considerations for pharmaceutical companies to keep in mind…
Zydus Lifesciences Chairman Pankaj Patel receives Padma Bhushan for contributions to trade and…
President of India Droupadi Murmu confers Padma Bhushan on Pankaj Patel, Chairman of Zydus Lifesciences, for his work in advancing…
Shionogi’s cefiderocol shows improved outcomes with early use in treating gram-negative infections:…
PROVE study reveals significantly improved outcomes with early use of cefiderocol in treating serious gram-negative infections,…
ASPA hosts MEA Open House in Dubai to advance anti-counterfeiting collaboration
ASPA strengthens regional engagement in Middle East and Africa with participation from 17 companies
Dr Reddy’s expands partnership with Sanofi to launch Beyfortus for RSV prevention in India
Dr Reddy’s to promote and distribute nirsevimab-based drug Beyfortus for RSV in newborns and infants
Morepen Laboratories receives CDSCO clearance for bioequivalence studies on Resmetirom
Morepen Laboratories advances Resmetirom development for NASH treatment following SEC approval
DP World achieves 65% renewable energy use in 2024, paving way for sustainable healthcare logistics
DP World’s latest sustainability report highlights its investment in green infrastructure and sustainable finance, supporting…
Zydus Lifesciences to Acquire 85.6% of Amplitude Surgical, block acquisition expected by Q3 2025
Zydus signs share purchase agreement to acquire majority stake in Amplitude Surgical, subject to regulatory approval and closing…
Biocon Biologics receives positive CHMP opinions for denosumab biosimilars Vevzuo and Denosumab BBL
European Medicines Agency’s CHMP recommends approval of Biocon Biologics' denosumab biosimilars for bone health indications